Clinical trials: 5-FU
Neuroendocrine Tumors
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY) are one of the main systemic treatments used, at least for advanced duodeno-pancreatic NETs, with a response rate of 30 to 40% and a…
- Trial name
- MGMT-NET (NCT03217097)
- Testing
- Oxaliplatin-based chemotherapy, Alkylating-based chemotherapy
- Where
- 19 sites in France
- Volunteers
- 116 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Neoplasms
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
The main purpose of this study is to evaluate how well olomorasib is tolerated and what side effects may occur when combined with other interventions in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)…
- Trial name
- NCT07814417
- Testing
- Olomorasib, Cetuximab, Oxaliplatin
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Esophageal Neoplasms
A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC
This is a perspective, multicenter,single arm, open label study to evaluate the efficacy and safety of treatment with CMNa combined with preoperatie concurrent chemoradiotherapy in patients with locally advanced squamous cell…
- Trial name
- NCT02721550
- Testing
- Sodium Glycididazole
- Where
- 9 sites in China
- Volunteers
- 2 people
- Sponsor
- Shandong Cancer Hospital and Institute
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
This phase Ib trial investigates the side effects and how well a shorter course of chemotherapy and radiation treatment (chemoradiotherapy) for 2 weeks instead of 5 weeks followed by standard chemotherapy works in treating…
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8
- Trial name
- NCT04523818
- Testing
- Capecitabine, Fluorouracil, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach…
- Trial name
- RAINFALL (NCT02314117)
- Testing
- Ramucirumab, Capecitabine, Cisplatin
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 645 people
- Sponsor
- Eli Lilly and Company
Hypopharyngeal Cancer
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
Hypopharyngeal cancer is an important part of head and neck cancer, with more than 80,000 new cases in 2018. And it is a highly aggressive cancer often diagnosed at an advanced stage.
- Trial name
- NCT04502641
- Testing
- Docetaxel, 5-fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Colon Cancer
Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.
The goal of this investigational, multicenter, open-label randomized, two-stage phase II study is to evaluate neoadjuvant pembrolizumab with a watch-and-wait approach in patients with localized deficient mismatch repair / high…
- Trial name
- PREMICES (NCT06646445)
- Testing
- Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery
- Where
- 10 sites in France
- Volunteers
- 60 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
This is a single-arm, open-label clinical trial designed to evaluate the efficacy and safety of irinotecan liposome (II), 5-FU/LV in combination with bevacizumab for the treatment of advanced colorectal cancer.
- Trial name
- NCT07123441
- Testing
- Bevacizumab,Irinotecan liposome (II),5-FU/LV
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sanjun Cai
Recurrent Colorectal Carcinoma, Progressive Colorectal Carcinoma
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
Phase 1b, safety, pharmacokinetic, and efficacy, multicenter, dose-escalating Study of Imprime PGG™ Injection dosed in combination with Cetuximab and concomitant irinotecan therapy.
- Trial name
- NCT00545545
- Testing
- Imprime PGG 2 mg/kg, Imprime PGG 4 mg/kg, Cetuximab
- Where
- 2 sites in Philippines
- Volunteers
- 32 people
- Sponsor
- HiberCell, Inc.
Esophageal Neoplasms, Carcinoma, Squamous Cell
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.
- Conditions
- Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00368329
- Testing
- Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent…
- Trial name
- NCT04223024
- Testing
- CCRT+Nimotuzumab, CCRT alone
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Incurable Colorectal Cancer, RAS-wild-type
Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
1. To evaluate efficacy, safety, and feasibility of maintenance therapy with Cetuximab combined with irinotecan or fluorouracil after Cetuximab plus irinotecan and fluorouracil(FOLFIRI) in patients with incurable colorectal…
- Trial name
- NCT02071069
- Testing
- Cetuximab, irinotecan, fluorouracil
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Tianshu Liu
Head and Neck Squamous Cell Carcinoma
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
The aim of this study is to evaluate the rate of living patients at 1 year with a quality of life criteria (no decrease) and reduced toxicities.
- Trial name
- OMET (NCT03070366)
- Testing
- Chemotherapy, Stereotactic radiotherapy
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Pancreas Cancer
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
The study's overall objectives are to evaluate the safety of anakinra in combination with standard chemotherapy regimens in patients with pancreatic ductal adenocarinoma, as well as to collect preliminary immune modulation and…
- Trial name
- NCT02021422
- Testing
- anakinra, Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Gastric (Stomach) Cancer, Gastric Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic…
- Conditions
- Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
- Trial name
- NCT06871527
- Testing
- fruquintinib + tislelizumab + FOLFOX
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cancer of Larynx
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
The purpose of this study is to learn how to identify early which patients will respond to chemotherapy plus radiation therapy in order to reduce the number of subjects who require surgery (followed by radiation therapy).
- Trial name
- NCT00599131
- Testing
- Cisplatin, Cetuximab, 5-Fluorouracil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
This phase II trial studies how well fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRI) together with panitumumab work in treating patients with colorectal cancer that expresses the RAS and B-Raf…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02508077
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Advanced Pancreatic Cancer
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer
The purpose of this study is to explore whether chemotherapy regimens guided by organoid drug sensitivity test can improve the outcomes of advanced pancreatic cancer.
- Trial name
- NCT04931381
- Testing
- Chemotherapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma
Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Claudin 18.2 (CLDN18.2) is a molecular target expressed in a subset of gastric and gastroesophageal junction (GEJ) adenocarcinomas.
- Trial name
- Zodiac-Neo (NCT07872722)
- Testing
- Zolbetuximab, Durvalumab, FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel)
- Where
- 4 sites in Japan
- Volunteers
- 29 people
- Sponsor
- National Cancer Center, Japan
Colorectal Cancer, Liver Metastases
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach.
- Trial name
- NCT05948072
- Testing
- mFOLFOX6 + Cetuximab, mFOLFOX 6
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.